Skip to main content

Korro Bio, Inc.

KRRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001703647

In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 8 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Korro Bio, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of KRRO: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders86358−25
Shares15.9M108.2K8.68M−7.07M (−44.9%)
Value$33.1M$229.0K$13.0M−$19.9M (−60.4%)

3 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (10)

Institutions that held Korro Bio, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to KRRO in Q2 2022
InstitutionSharesValue% of portfolio
Ergoteles LLC156,300$234.0K0.01%
Citadel Advisors LLC122,638$183.0K0.00%
Waldron Private Wealth LLC70,670$106.0K0.01%
Prudential Financial Inc23,700$36.0K0.00%
Qube Research & Technologies Ltd23,256$35.0K0.00%
Essex Financial Services, Inc.20,000$30.0K0.00%
LMR Partners LLP11,538$17.0K0.00%
Verition Fund Management LLC10,267$15.0K0.00%
City State Bank1,000$1.00K0.00%
Credit Suisse AG106$00.00%

Sold out (35)

Institutions that held Korro Bio, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Not filed for Q2 2022 yet (3)

Institutions that held Korro Bio, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding KRRO in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Parametric Portfolio Associates LLC72,705$154.0K
Susquehanna Fundamental Investments, LLC31,668$67.0K
Amalgamated Financial Corp.3,868$8.00K